On page 2152, in the second paragraph under “Discussion,” the investigators “observed better survival in gilteritinib-arm DNMT3A/NPM1 comutated patients,” not “c-mutated patients.”
. 2022 Nov 17;6(22):5886. doi: 10.1182/bloodadvances.2022009077
Smith CC, Levis MJ, Perl AE, et al. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6(7):2144-2155.
Collection date 2022 Nov 22.
© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
PMCID: PMC9681930 PMID: 36378495
This corrects the article "Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib" on page 2144.